|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||7.38 - 7.60|
|52 Week Range||6.57 - 14.00|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
TORONTO , May 30, 2019 /CNW/ - Abacus Health Products, Inc. (ABCS.CN) ("Abacus" or the "Company") reported its financial results today for the first quarter ended March 31, 2019 . CBD CLINIC continued to perform well with revenue increasing 148% YoY, from $1,433,243 to $3,553,751 , and an increase of 23% over the fourth quarter of 2018, from $2,886,412 . Purchase orders received to date represent over 2,000 retail pharmacy and supermarket locations across 11 states.
WOONSOCKET, RI and TORONTO, May 23, 2019 /PRNewswire/ - Abacus Health Products, Inc. (ABCS.CN) ("Abacus" or the "Company") today announced that renowned Hollywood fitness trainer and nutritional expert, Harley Pasternak, will be working with the Company to increase public awareness of its CBDMEDIC™ line of pain relief and skincare products. Pasternak holds a Master of Science in Exercise Physiology and Nutritional Sciences from the University of Toronto and an Honors Degree in Kinesiology from the University of Western Ontario.
Abacus Health Products Announces Release Date, Conference Call and Webcast Details for 2019 First Quarter Financial Results
WOONSOCKET, RI and TORONTO, May 10, 2019 /CNW/ - Abacus Health Products, Inc. (ABCS.CN) ("Abacus" or the "Company") today announced further growth in the distribution and availability of their line of CBDMEDIC™ products. "These purchase orders, which range from six to twelve unique SKUs across our pain relief and therapeutic skincare lines, demonstrate the continued strong interest by retail chains to bring CBDMEDIC™ products onto their shelves," said Perry Antelman , CEO of Abacus. Further, a 2018 research report by Allied Market Research estimated the global topical pain relief market to be approximately US$7.4 billion in 2017.
TORONTO , Feb. 28, 2019 /CNW/ - Abacus Health Products, Inc. (CSE:ABCS) ("Abacus" or the "Company") today announced its first purchase order received from a major United States retail chain. "This purchase order marks an important milestone in our growth strategy of securing major US retail chains to distribute our products," said Perry Antelman , CEO of Abacus. Abacus has developed a range of innovative products based on patent-pending technologies which combine natural and organic ingredients, including a cannabinoid-rich hemp extract containing CBD from the Cannabis sativa L plant.